ChristopherGasinkMD

Physician

Dr. Gasink is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Spruce St
Fl 3
Philadelphia, PA 19104
Phone+1 215-349-8222

Fax+1 215-615-0500

University of Pennsylvania Health SystemFellowship, Gastroenterology, 2001 - 2004
University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
University of Virginia School of MedicineClass of 1998

PubMed

805 citations
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn, Christopher Gasink, Long Long Gao, Marion Blank, Jewel Johanns
The New England Journal of Medicine. 2012-10-17
963 citations
Effector and memory CD8 + T cell fate coupled by T-bet and eomesodermin
Andrew M. Intlekofer, Naofumi Takemoto, E. John Wherry, Sarah A. Longworth, John T Northrup
Nature Immunology. 2005-11-06
126 citations
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Stephen B. Hanauer, William J. Sandborn, Brian G. Feagan, Christopher Gasink, Douglas Jacobstein
Journal of Crohn's & Colitis. 2020-01-01

JnJ Tremfya Receives USFDA Approval for Adults with Moderately to Severely Active Ulcerative ColitisSeptember 11th, 2024
TREMFYA® (Guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson's Leadership in Inflammatory Bowel DiseaseSeptember 11th, 2024
TREMFYA® (Guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson's Leadership in Inflammatory Bowel DiseaseSeptember 11th, 2024
Join now to see all